NASDAQ:MTSR Metsera Q1 2025 Earnings Report $30.30 -0.57 (-1.85%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Metsera EPS ResultsActual EPS-$1.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMetsera Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMetsera Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Metsera Earnings HeadlinesWe're Hopeful That Metsera (NASDAQ:MTSR) Will Use Its Cash WiselyJuly 31, 2025 | finance.yahoo.comMetsera shares tumble as quarterly loss worse than expectedJuly 28, 2025 | uk.investing.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 14 at 2:00 AM | The Oxford Club (Ad)Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio ProgressJuly 28, 2025 | globenewswire.comMetsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes AssociationJuly 14, 2025 | finance.yahoo.comMetsera Clears Key Benchmark, Hitting 90-Plus RS RatingJuly 9, 2025 | msn.comSee More Metsera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email. Email Address About MetseraMetsera (NASDAQ:MTSR), Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.View Metsera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings Beat Upcoming Earnings Palo Alto Networks (8/18/2025)Home Depot (8/19/2025)Medtronic (8/19/2025)Analog Devices (8/20/2025)Synopsys (8/20/2025)Lowe's Companies (8/20/2025)TJX Companies (8/20/2025)Intuit (8/21/2025)Workday (8/21/2025)Alibaba Group (8/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access